Workflow
23andMe (ME)
icon
Search documents
23andMe Reports First Quarter Fiscal 2025 Financial Results
GlobeNewswire News Room· 2024-08-08 20:05
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter of fiscal year 2025 (FY25), which ended June 30, 2024. Key Results and Recent Developments Reported total revenue of $40 million in the first quarter of fiscal 2025, a decrease of approximately 34% over the same period in the prior year primarily due to lower research revenue after the conclusion of the G ...
23andMe Special Committee responds to CEO's take-private proposal
Newsfilter· 2024-08-02 12:00
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, in response to Ms. Wojcicki's previously disclosed preliminary non-binding indication of interest to acquire all of the outstanding shares of 23andMe not owned by her or her ...
23andMe Special Committee responds to CEO's take-private proposal
GlobeNewswire News Room· 2024-08-02 12:00
Core Viewpoint - The Special Committee of 23andMe Holding Co. has expressed disappointment with CEO Anne Wojcicki's preliminary proposal to acquire outstanding shares, citing lack of premium, committed financing, and conditional nature of the offer as key issues [2][3]. Group 1: Proposal Evaluation - The proposal from Anne Wojcicki offers cash consideration of $0.40 per share for Class A and Class B Common Stock, which does not provide any premium over the closing price on July 31 [1][2]. - The Special Committee views the proposal as insufficient and not in the best interest of non-affiliated shareholders, requesting the withdrawal of any opposition to alternative transactions [2][4]. Group 2: Expectations for Revised Proposal - The Special Committee expected a fully-financed and actionable proposal that aligns with the interests of non-affiliated shareholders, and is willing to provide additional time for a revised proposal [3][4]. - Any revised proposal must include fully committed financing and should not impose deal expenses on unaffiliated shareholders, while remaining subject to approval by the Special Committee and a majority of unaffiliated shareholders [4][5]. Group 3: Future Actions - In the absence of a satisfactory revised offer, the Special Committee plans to engage a consultant to develop a revised business plan aimed at achieving a more sustainable financial profile and profitability [5].
23andMe Announces CEO's Take-Private Proposal
Newsfilter· 2024-08-01 12:00
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, has received a preliminary nonbinding indication of interest from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of 23andMe not owned by her or her affiliates or any other stockholder that she invites to roll over their shares for cash consideration of $0.40 per sha ...
23andMe CEO files proposal to take company private as stock craters
CNBC· 2024-07-31 22:11
A sign is posted in front of the 23andMe headquarters in Sunnyvale, California, on Feb. 1, 2024. Anne Wojcicki, CEO of 23andMe, has submitted a proposal to take the genetic testing company private as its stock price continues to hover below $1. Wojcicki said she was prepared to acquire all of 23andMe's outstanding shares of common stock in cash for 40 cents per share, according to a Wednesday filing with the U.S. Securities and Exchange Commission. She expressed interest in acquiring the company in April, s ...
23andMe to Report Q1 FY2025 Financial Results
Newsfilter· 2024-07-25 20:45
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's ...
23andMe to Report Q1 FY2025 Financial Results
GlobeNewswire News Room· 2024-07-25 20:45
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's ...
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
Newsfilter· 2024-07-25 11:30
The de-identified data from the study will be made available to approved researchers, and access to the scientific database will be available to nonprofit researchers and institutions at no cost. Behind every devastating statistic are people from communities across the U.S. impacted by lung cancer. Through this collaboration, advocacy organizations, lung cancer survivors and advocates, and 23andMe hope ultimately to help advance research toward finding a cure for this disease. "Studying the genetics of lung ...
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
GlobeNewswire News Room· 2024-07-25 11:30
Core Insights - Lung cancer remains a critical area of unmet need despite advances in treatment options, with the disease being the leading cause of cancer deaths in the U.S. [4][11] - The Lung Cancer Genetics Study aims to enhance research by collecting genetic, clinical, and patient-reported data to improve detection, risk reduction, and care for lung cancer patients [8][11] Company Overview - 23andMe Holding Co. is a genetic health and biopharmaceutical company that collaborates with 20 lung cancer advocacy organizations to conduct the Lung Cancer Genetics Study [4][9] - The study will utilize the 23andMe research platform to gather critical data from participants, which will be made available to approved researchers at no cost [5][12] Study Details - The study aims to recruit 10,000 individuals diagnosed with lung cancer, with no restrictions on cancer type, stage, gender, or smoking status [14] - Participants will receive 23andMe kits at no cost, and the study seeks to reflect the diversity of communities affected by lung cancer [8][14] Research Goals - The study intends to fill a gap in comprehensive databases that connect genetic, clinical, and patient-reported data, ultimately improving treatment and care for lung cancer [8][11] - It is estimated that in 2024, 234,000 new lung cancer cases will be diagnosed in the U.S., highlighting the urgent need for research [11]
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
Newsfilter· 2024-06-28 11:00
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health's clinicallyvalidated and cost-effective blood metabolomics panel with a cohort of 23andMe members. 23andMe currently offers its annual members the option for blood testing and provides interactive tools like He ...